The UK and US have agreed to a major bilateral deal that will guarantee zero tariffs on UK medicine shipments entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to raise expenditure on pharmaceuticals through the National Health Service (NHS). This pledge ensures that tariffs on these vital goods will be held at nothing for a period of three years.
This agreement is in response to previous threats to significantly raise duties on patented pharmaceutical imports, with figures mentioned as high as 100%.
"This arrangement with the Britain strengthens the international landscape for cutting-edge drugs and establishes much-needed balance to American-British drug exports," an announcement said.
Economic Importance
Drugs constitute one of the Britain's most significant exports to the US, which is easily the largest buyer for major British pharmaceutical firms.
Trade data indicate that in the one-year period leading up to the third quarter, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This amount made up nearly one-fifth of total UK exports in that timeframe.
"This deal secures jobs, boosts capital expenditure and paves the way for the UK to establish itself as a global hub for biotech and pharma," a minister stated.
Detailed NHS Changes
The agreement includes several notable pledges from the British government:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a target to double total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to prevent overspending will be capped at 15%. In the past, refunds exceeded 20%.
Industry Background
The pact comes amid a long-running row between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
These tensions were exacerbated by claims that American customers were paying significantly more for the equivalent treatments than people in the Britain and the EU.
In recent months, several large drug company projects in the UK have been paused or cancelled, while substantial expansions have been announced toward US facilities.
One official stated that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had shrunk as a proportion of its total funding over the last ten years.
